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胸腺嘧啶 (2)，2,4-喹唑啉二酮 (3), 环-(亮氨酸-酪氨酸) (4), 异烟酰胺 (5), 环-(脯氨
酸-酪氨酸) (6), 环-(脯氨酸-缬氨酸) (7), 环-(丙氨酸-异亮氨酸) (8), 环-(苯丙氨酸-脯
氨酸) (9), 环-(异亮氨酸-缬氨酸) (10)，1,2,2-三-1H-吲哚-3-基乙酮 (11), N-[1-羟甲基
-2-[4-乙酰氨基苯基]- 2-(1H-吲哚-3-基)乙基]-2,2-二氯乙酰胺 (12), 环-(色氨酸-酪氨




































Secondary metabolites of the culturable microorganisms in nature have been becom- 
ing a most important source of some medicinal products and new bioactive compounds 
for medicinal usage. It has been known that only less than 1% of total microorganisms in 
nature are culturable by traditional pure culture technique, yet the absolute majority of 
microbes in nature have not been studied and utilized. Because of the particular extreme 
conditions that include high-pressure, low temperature, oxygen deficit, exteme PH value, 
high salinity, high metallicity, empty illumination, poor nutrition, high halogen the 
deep-sea microorganisms live in, they can produce secondary-metabolites with novel 
structures, distinctive functions, slight side-effects. The secondary-metabolite is one of 
the most important sources in hunting for novel anti-tumor drugs.Metagenomic library 
construction provided a powerful tool for exploring and accessing the genetic information 
and functional diversity of non- culturable microorganisms in the environment, which is 
also useful, through facilitating the cloning and expressing of the aimed foreign DNA in 
the culturable hostmicrobes to obtain bioactive metabolites encoded by the genes of 
uncultured microbes. Metagenomic approach can be used to overcome at least partially 
the bias, gain access to new scientific discoveries and genetic resources. 
In this study, 14 compounds were searated from clone 1and clone 6 by various 
chromatographic metheds,such as macroporous resin, silica gel, ODS reversed-phase 
column, HPLC and so on.  
According to their physico-chemical properties and data of NMR(1H-NMR, 
13C-NMR), their structures can be identified as: Uracil (1), Thymine (2), 4-Pyridinecar- 
2,4(1H,3H)-Quinazolinedione (3), Cyclo(Leu-Tyr) (4), boxamide (5), Cyclo(Pro-Tyr) (6), 
Cyclo(Pro-Val) (7), Cyclo(Ala-Ile) (8), Cyclo(Phe-Pro) (9), Cyclo(Ile-Val) (10), 
1,2,2-tri-1H-indol-3-ylethanone(11), N-[2-[4-(acetylamino)phenyl]-1-(hydroxymethyl)-2- 
(1H-indol-3-yl)ethyl]-2,2-dichloroacetamide (12) ,Cyclo(Trp-Tyr) (13) ,Cyclo(Phe-Tyr) 
(14). Compound 11 and 12 are new compounds, and compound 11 have good anti-tumor 
activities. 






























ODS        Octadecylsilyl 
HPLC       High Performance liquid chromatography 
RP-HPLC    Reversed phase high performance liquid 
UV         Ultraviolet 
IR          Infrared 
ESI-MS     Electronspray ionization-mass spectrum 
m/z         Mass-to-charge ratio 
DEPT       Distortionless enhancement by Polarization transfer  
COSY      Correlated 2D spectroscopy 
HMBC      Heteronuclear multiple-bond correlation 
HSQC      Heteronuclear single-quantum correlation 
DMSO      Dimethyl sulfoxide 
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无脊椎动物中发现了约15000种具有结构多样性和生物活性的天然产物[7] , 其中, 
三类源自于海洋微生物的药物已经投放到国际药品市场。与此同时, 研究人员正对
十多种源自海洋的药物进行临床试验和临床前期实验观察[3] , 其中包括来自于海绵



















高度的结构相似性, 近的研究成果也充分证明了这个推论[ 4,5] 。因此, 海洋环境中
的化学多样性是天然产物药物开发的一个重要目标。目前, 很多资源已投入这个领
域的研究前沿, 期望解决对新颖抗生素类药物和其它高效天然药物越来越迫切的需








由海洋生物( 包括微生物) 产生的生物活性物质在海洋小生态系统中存量极微, 
比如在海绵中, 生物活性物质通常仅痕量存在。大规模的样品采集和化合物分离提
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